These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1481188)

  • 1. Oesophageal dissection after thrombolytic treatment for myocardial infarction.
    Jishi F; Sissons CE; Silverstone EJ; Coakley JF; Fraser F
    Thorax; 1992 Oct; 47(10):835-6. PubMed ID: 1481188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rash after treatment with anistreplase.
    Burrows N; Jones RR
    Br Heart J; 1990 Oct; 64(4):289-90. PubMed ID: 2223309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypersensitivity vasculitis after thrombolytic therapy with APSAC (anisoylated plasminogen streptokinase activator complex). Presentation of a clinical case and review of the literature].
    Gianni R; Benucci M; Santoro E; Nenci G; Baruffi MC; Cappelletti C
    Ann Ital Med Int; 1994; 9(2):105-6. PubMed ID: 7917762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete dysphagia after thrombolytic treatment for myocardial infarction.
    Mosimann T; Terracciano L; Sieber C; Rappo F
    Postgrad Med J; 2000 Dec; 76(902):795-6. PubMed ID: 11085774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting intramural hematoma of esophagus after thrombolytic therapy: a case report.
    Hajsadeghi S; Agah S; Iranpour A; Chehrehgosha H; Ghanooni AH; Forghani F
    Asian Cardiovasc Thorac Ann; 2015 Feb; 23(2):224-6. PubMed ID: 24585301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term comparative study of anistreplase versus streptokinase in acute myocardial infarction.
    Silber H; Hausmann MJ; Katz A; Gilutz H; Zucker N; Ovsyshcher I
    Angiology; 1992 Jul; 43(7):572-7. PubMed ID: 1626735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.
    Brügemann J; van der Meer J; Takens BH; Hillege H; Lie KI
    Br Heart J; 1990 Dec; 64(6):355-8. PubMed ID: 2271340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Side effects of thrombolytic therapy in patients with myocardial infarction].
    Agostoni A; Gardinali M
    Cardiologia; 1995 Dec; 40(12):899-908. PubMed ID: 8901040
    [No Abstract]   [Full Text] [Related]  

  • 9. Guillain-Barré syndrome after acute myocardial infarction treated with anistreplase.
    Ancillo P; Duarte J; Cortina JJ; Sempere AP; Clavería LE
    Chest; 1994 Apr; 105(4):1301-2. PubMed ID: 8162787
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombolytic therapy for coronary occlusion.
    Thompson PL
    Med J Aust; 1992 Jul; 157(2):75-7. PubMed ID: 1630392
    [No Abstract]   [Full Text] [Related]  

  • 11. Embolic cerebral infarction and gastrointestinal hemorrhage following thrombolytic therapy for acute myocardial infarction.
    Chang MC; Lee AY; Chang WF; Chen TJ
    Echocardiography; 2002 Feb; 19(2):139-41. PubMed ID: 11926976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult respiratory distress syndrome following thrombolytic therapy with APSAC for acute myocardial infarction.
    Le SP; Chatterjee K; Wolfe CL
    Am Heart J; 1992 May; 123(5):1368-9. PubMed ID: 1575153
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical risks of thrombolytic therapy.
    Califf RM; Fortin DF; Tenaglia AN; Sane DC
    Am J Cardiol; 1992 Jan; 69(2):12A-20A. PubMed ID: 1729875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Bucknall C; Darley C; Flax J; Vincent R; Chamberlain D
    Br Heart J; 1988 Jan; 59(1):9-11. PubMed ID: 2963655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic therapy in acute myocardial infarction.
    Paspa PA; Movahed A
    Am Fam Physician; 1992 Feb; 45(2):640-8. PubMed ID: 1739049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ; Grimm AM; Hopkins LE
    Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol embolism after intravenous anisoylated plasminogen streptokinase activator complex (APSAC).
    Beutler JJ; Sulzer MA; van Stralen R
    Neth J Med; 1991 Dec; 39(5-6):373-4. PubMed ID: 1803250
    [No Abstract]   [Full Text] [Related]  

  • 19. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group.
    Clin Trials Metaanal; 1993 Nov; 28(6):317-28. PubMed ID: 10150180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.